Table 2

Baseline plasma copeptin and risk for LEA during follow-up

Cohorts with type 1 diabetesPCohorts with type 2 diabetesP
HR or sHR95% CIHR or sHR95% CI
Crude1.911.47–2.45<0.00011.791.52–2.09<0.0001
Model 11.801.31–2.470.00031.531.28–1.81<0.0001
Model 21.891.28–2.820.0021.421.15–1.740.001
Model 31.821.28–2.610.0011.641.38–1.940.001
  • HR and sHR computed for 1 SD of log[copeptin] by Cox proportional hazards survival regression analysis (HR) or competing risk regression analyses (sHR). Model 1 for cohorts with type 1 diabetes: adjustment for cohort membership, sex, age, duration of diabetes, systolic blood pressure, HbA1c, use of diuretics and of blood pressure–lowering drugs, and previous history of myocardial infarction and LEA at baseline. Model 1 for cohorts with type 2 diabetes: adjustment for cohort membership; sex; age; duration of diabetes; arterial hypertension; HbA1c; total cholesterol; HDL cholesterol; use of insulin, ACE inhibitors, angiotensin receptor blockers, diuretics, blood pressure–lowering drugs, antiplatelet or anticoagulation drugs, or lipid-lowering drugs; and previous history of LEA at baseline. Model 2 for all cohorts: model 1 adjustments plus adjustment for eGFR and UAC at baseline. Model 3 for all cohorts: death from all causes as a competing risk over model 2. P < 0.05 is significant.